Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice  by Haddad, Luciana B.P. et al.
ORIGINAL ARTICLE
Pancreatic fistula after pancreaticoduodenectomy: the conservative
treatment of choice
Luciana B.P. Haddad1, Olivier Scatton2, Bruto Randone2, Wellington Andraus1, Pierre-Philippe Massault2,
Bertrand Dousset2 & Olivier Soubrane2
1Digestive Surgery Division, University of São Paulo School of Medicine – Department of Gastroenterology, Brazil and 2Liver Department, Cochin Hospital,
AP-HP, Paris, France
Abstract
Background: A pancreatic fistula (PF) is the most common complication after pancreaticoduodenec-
tomy (PD), and its reported incidence varies from 2% to 28%. The aim of the present study was to analyse
the treatment of a complicated PF comparing the surgical approach with conservative techniques.
Methods: From January 2000 through to August 2006, 121 patients were submitted for PD. The study
consisted of 70 men and 47 women, with a median age of 60 years (SD  12). The main indications for
PD were pancreatic duct carcinoma in 52 patients (44.5%), ampullary carcinoma or adenoma in 18
(15.4%) and islet cell tumour in 11 (9.4%). Reconstruction by pancreatogastrostomy was performed in 65
patients (55.6%), and pancreatojejunostomy in 52 patients (44%).
Results: Thirty-five patients (30%) developed a PF. Amongst these, 20 were managed conservatively
and 14 were reoperated. These two groups of patients were compared with patients without a PF for
analysis. There was no significant difference in the mean age, the gender ratio, American Society of
Anesthesiologists (ASA) classification, surgical time and blood replacement, number of associated pro-
cedures, vascular resection and type of reconstruction between the three groups. There were five
post-operative deaths (4.2%), three patients (21.4%) in the surgical treatment group (P < 0.01). Mean total
number of complications (P = 0.02) and mean length of hospital stay (P < 0.001) were greater in the
surgical group. The medium delay between the pancreatic resection and reoperation was 10 days (range,
3–32 days). Completion splenopancreatectomy was required in five patients whereas conservative
treatment including debridement and drainage was applied in nine patients.
Conclusion: The surgical approach for a PF is associated with a higher mortality and morbidity. There
is no advantage in performing completion pancreatectomy (CP) instead of extensive drainage as a result
of the same mortality and morbidity rates and the risk of endocrine insufficiency. In cases of complicated
PF, radiological or surgical conservative treatment is recommended.
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Introduction
Over the past three decades, operative mortality rates after pan-
creaticoduodenectomy (PD) have decreased dramatically.1–3 An
increase in experience and continuous improvements in surgical
techniques have led to this decline, and in many high-volume
centres the mortality rate is lower than 4%.4–8 However, the post-
operative morbidity rate is still high, between 30% to 50%.9–12 A
pancreatic fistula (PF) is the most common complication after
PD, and its reported incidence varies from 2% to 28%.7,9–17 A great
deal of effort has been made to minimize its occurrence, using
different methods for reconstruction, mainly drainage into either
a jejunal loop (pancreaticojejunostomy) or the remaining
stomach (pancreaticogastrostomy). Occlusion of the pancreatic
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stump without any anastomosis in cases of small atrophic pan-
creas, biological adhesives to seal the anastomosis, somatostatin
analogues to inhibit pancreatic secretion or a number of different
anastomosis surgical techniques have also already been used to
reduce the PF rate and none of these have demonstrated a clear
advantage.15,18–29
Developments in diagnosis methods and radiological interven-
tion techniques have been responsible for an increase in the con-
servative management of PF. However, the leakage of pancreatic
anastomosis can lead to bleeding from adjacent large vessels,
severe pancreatitis, peritonitis and/or sepsis. In these cases, the
conservative approach is not possible, and the risk of post-
operative death is high.2,3,5,6,12,16,30,31,33
Surgical management of a complicated PF can vary from simple
drainage of the anastomotic region to completion pancreatectomy
(CP) in the case of uncontrollable anastomotic leakage and peri-
tonitis.32 Favourable outcomes after CP have been reported,32,33
but an important disadvantage of this option is pancreatic endo-
crine insufficiency. The aim of the present study is to analyse the
treatment of a complicated PF comparing the surgical approach
with conservative techniques.
Patients and methods
We reviewed the medical records of 121 patients who underwent
PD between 1 January 2000 and 31 August 2006. Four patients
without anastomosis of the pancreatic remnant were not
included. Data collection was performed retrospectively using
operation records, patient’s files and discharge letters.
There were 70 men and 47 women, with a median age of 60
years (SD 12). Indication for PD was pancreatic duct carcinoma
in 52 patients (44.5%), ampullary carcinoma or adenoma in 18
(15.4%), islet cell tumour in 11 (9.4%), intraductal papillary
mucinous neoplasm in 4 (3.4%) duodenal carcinoma in 4 (3.4%),
cystoadenoma in 2 (1.7%) and chronic pancreatitis in 8 (6.8%). In
nine (7.7%) cases, PD was performed as part of a more extended
resection of advanced cholangiocarcinoma or gallbladder cancer.
Other indications existed in nine patients (7.7%), such as peri-
pancreatic metastasis or invasion of colonic, gastric or renal cell
cancer.
Surgical technique
None of the 117 resections had pylorus preservation and extend of
gastric resection was not standardized. There was, however, a
tendency towards a limited antrectomy. Reconstruction by pan-
creatogastrostomy was performed in 65 patients (55.6%) and
pancreatojejunostomy in 52 patients (44%). After PD, choice of
the type of reconstruction (pancreatogastrostomy or pancreatoje-
junostomy) was decided according to the surgeon’s preference
and was not influenced by the consistence of the pancreas. In cases
of cancer, a standard peripancreatic lymphadenectomy was per-
formed, without extended retroperitoneal lymph node dissection.
A silicone drain was routinely placed near the pancreatic anasto-
mosis in all patients. If the post-operative course was uneventful,
a CT-scan was systematically performed on post-operative day
(POD) 7 and in the absence of pathological findings the drain was
removed. The presence of gas bubbles and/or liquid collection
near the anastomosis were considered as radiological signs of PF
even in the absence of amylase-rich fluid in the drain. In this
situation drain withdrawal was delayed.
Tube gastrostomy and a feeding jejunostomy were not used.
Thirteen patients (11.1%) had vascular resection and 8 (6.8%)
had additional major organ resections (e.g. liver or colonic
resection).
Complications
A PF was defined as a drain output of any measurable volume of
fluid after POD 3 with amylase content greater than three times
the serum amylase activity (CB). Post-operative mortality was
defined as death occurring in the first 30 post-operative days or
before discharge from the hospital. Delayed gastric emptying was
defined as intolerance to oral intake and need for nasogastric
decompression after the 7th post-operative day.
Other complications were categorized and defined as any of the
following: intra-abdominal abscess (fluid requiring drainage and
with positive bacterial culture); wound infection; post-operative
bleeding (requiring transfusion, endoscopic or operative inter-
vention); bile leakage (bilious drainage from intra-operatively
placed drains or bile collection requiring drainage); cardiac (myo-
cardial infarction or new-onset arrhythmia requiring interven-
tion); pulmonary (pneumonia, effusion requiring drainage, or
reintubation); sepsis (fever, leukocytosis, or bacteremia requiring
medical and/or surgical intervention); and reoperation in the first
30 postoperative days or before discharge from the hospital.
Pancreatic leakage was generally treated by maintenance of the
drain placed near the pancreaticodigestive anastomosis. Per-
cutaneous drainage was performed if the patient developed a
concomitant intra-abdominal abscess or fluid collection
diagnosticated by tomography. Relaparotomy was performed for
post-operative haemorrhage and intra-abdominal collection
when the interventional methods were not possible or the patient
showed clinical deterioration.
In the absence of reliable guidelines, the management of the PF
at the time of relaparatomy was left to the discretion of the oper-
ating surgeon. However, conservative treatment, including a thor-
ough peritoneal lavage, drainage and the control of sepsis using
large spectre antibiotherapy, was the preferred approach whenever
considered possible. In the presence of massive peritoneal con-
tamination as a result of complete disunion of the pancreatic
anastomosis CP was undertaken.
Statistical analysis
Data analyses were performed using SPSS® software (SPSS,
Chicago, IL, USA). For statistical comparisons of the patients
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groups, a two-tailed c2 and t-test were used. Quantitative variables
were tested using a Mann–Whitney U-test. Values of P < 0.05 were
considered significant.
Results
Management of pancreatic leakage
Thirty-five patients (30%) developed PF. Amongst these, 20 were
managed conservatively and 14 were reoperated. These two
groups of patients were compared with patients without PF for
analysis (Table 1). The conservative treatment included the main-
tenance of the drain placed at the time of operation in 14 patients
(70%) and percutaneous drainage in the other 6 (30%). Mean age,
gender ratio and American Society of Anesthesiologists (ASA)
classification were similar in the three groups. The percentage of
malignant pathology was also similar (Table 2).
Intra-operative parameters are given in Table 2. There was no
significant difference in the surgical time and blood replacece-
ment between the three groups. Pancreas texture, Wirsung diam-
eter, number of associated procedures and vascular resection rate
were similar. The different types of pancreatic reconstruction were
not related to PF occurrence and reoperation.
There were five postoperative deaths for the entire series, with
an overall mortality rate of 4.2%. Two deaths occurred in the
group without PF (2.4%), as a result of mesenteric artery throm-
bosis and severe pneumonia, respectively. Three patients (21.4%)
died in the surgical treatment group (P < 0.001). There was no
mortality in group 2. Post-operative complications, including PF,
occurred in 54 out of the 117 patients, with an overall post-
operative morbidity rate of 46.1%. The mean total number of
complications for the group without PF was 0.36  0.5, com-
pared with 0.8  0.77 (P = 0.002) for conservative treatment
group and 2.21  0.73 (P < 0.001) for the surgical group,
excluding PF itself. The mean length of hospital stay for the
group without PF was 21  9 days, 42  17.5 days for the
Table 1 Groups characteristics
No of PF
(n = 82) (70%)
PF conservative
treatment
(n = 21) (18%)
PF surgical
treatment
(n = 14) (12%)
P
Gender (male : female) 44 : 38 15 : 6 10 : 4 0.450
Age, mean (range), years 59 (22–80) 62 (45–83) 59 (43–82) 0.600
ASA
I 37 (45) 8 (38) 6 (43) 0.663
II 41 (50) 13 (62) 8 (57)
III 4 (5) 0 (0) 0 (0)
Malignancy 71 (87) 16 (76) 12 (85,7) 0.496
PF, pancreatic fistula; ASA, American Society of Anesthesiologists
Values in parentheses are percentages unless indicated otherwise
Table 2 Intra-operative parameters
No of PF
(n = 82) (70%)
PF conservative
treatment
(n = 21) (18%)
PF surgical
treatment
(n = 14) (12%)
P
Surgical time, min 372 (240–720) 325.5 (240–600) 450 (300–670) 0.233
Red blood cells units transfusions 0.7 (0–12) 0,6 (0–5) 0,7 (0–4) 0.952
Pancreas texture
Hard 52 (63.5) 8 (38) 7 (50) 0.094
Soft 30 (36.5) 13 (62) 7 (50)
Wirsung diameter
<5 mm 36 (44) 12 (57) 9 (64) 0.257
>5 mm 46 (56) 9 (43) 5 (36)
Associated procedure 3 (3.6) 3 (14) 2 (14.2) 0.114
Vascular resection for tumour infiltration 11 (13.4) 1 (4,7) 1 (7.1) 0.467
Reconstruction 0.245
Pancreatogastrostomy 49 (60) 12 (57) 5 (36)
Pancreatojejunostomy 33 (40) 9 (43) 9 (64)
PF, pancreatic fistula
Values in parentheses are percentages, unless indicated otherwise
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conservative treatment group and 63  27 days for the surgical
group (P < 0.001) (Table 3).
In the surgical group, there were significant increases in the
following complications: delayed gastric emptying, intra-
abdominal bleeding and sepsis. There were no differences in rates
of wound infection, biliary fistula, cardiac and pulmonary com-
plications (Table 3).
Reoperation for PF
The mean age of the patients was 59 years (22–80 years). There
were 10 men (71%) and 4 women (29%). Patients were preopera-
tively scored as ASA I (six patients) or ASA II (eight patients).
Surgical findings of the 14 patients that were submitted for relap-
arotomy are detailed in Table 4. The medium delay between pan-
creatic resection and reoperation was 10 days (3–32 days).
Overall, completion splenopancreatectomy was required in five
patients, whereas conservative treatment, inclunding debridement
and drainage, was applied in nine patients. Three patients (14.2%)
died in the early post-operative period (8, 16 and 20 days after
surgery) as a result of multiorgan failure and sepsis. All of them
showed diffuse peritonitis at the time of reoperation, two patients
were submitted for completion pancreatectomy and the other one
for debridement and drainage.
Seven patients had post-operative medical complications: pneu-
mopathy (n = 3), renal failure (n = 2), cardiac arrhythmia (n = 1)
and mental confusion (n = 1). Six patients (43%) had delayed
gastric emptying. Mean hospital stay was 63  27 days for
survivors.
Discussion
The International Study Group on Pancreatic Fistula Definition
(ISGPF) has recently proposed a standardized definition of PF
which seems to be widely accepted.34 In this classification, three
grades of severity have been described. Overall, any fistula that
requires reoperation is classified as Grade C. However, in this
latter group of patients, two situations should be distinguished
depending on a finding of localized sepsis or diffuse peritonitis.
Although surgical conservative treatment is mainly used in the
case of localized collection, the management of diffuse peritonitis
still remains ill defined. In the last decade, conservative treatment
has been suggested instead of CP. In our study, we analysed the
two types of treatment and our results support the use conserva-
tive management.
Using a non-restrictive definition of PF, according to the ISGPF
proposition, 30% of our patients experienced pancreatic leakage.
Most of them were grade A or B (21/35). However, a remaining
large proportion of PF (grade C) was reoperated. However, com-
parative analyses of preoperative and intra-operative data failed to
predict severity of PF. Overall, mortality and morbidity, especially
delayed gastric emptying, were significantly greater in the cases of
reoperation for PF. Consequently, the hospital stay was longer in
such cases. We showed that reoperation for PF has a significant
deleterious impact on post-operative course as compared with
non-surgical management.
In the situation where surgery seems mandatory, two strategies
are available: CP or conservative treatment. Initially, CP was the
main surgical approach reported for the treatment of complicated
PF. In the last decade, this treatment has been restricted to patients
with peritonitis. At the present time, the use of CP is under debate
whereas conservative management has emerged as a salvage solu-
tion equally efficient to CP. The two main arguments to perform
CP are sterilization of the source of infection and the decreased
need for reoperation.32,33 However, CP is technically demanding,
leading in most cases to splenectomy, and more rarely to total
Table 3 Mortality and morbidity
No of PF
(n = 82) (70%)
PF conservative
treatment
(n = 21) (18%)
PF surgical
treatment
(n = 14) (12%)
P
Post-operative hospital stay (days) 21  9 42  17.5 63  27 <0.001a
0.008b
No. of complications,c mean  SEM 0.36  0.5 0.80  0.77 2.21  0.73 <0.001a
0.002b
Delayed gastric emptying 6 (7.3) 7 (33.3) 10 (71.4) <0.001
Wound infection 4 (4.8) 2 (9.5) 2 (14) 0.377
Biliary fistula 4 (5.7) 2 (9.5)) 1 (7.1) 0.712
Abdominal bleeding 4 (4.8) 1 (4.7) 4 (28.5) 0.008
Cardiac 3 (3.6) 1 (4.1) 1 (7.1) 0.249
Pulmonary 3 (3.6) 0 3 (21.4) 0.510
Sepsis 3 (3.6) 0 4 (28.5) <0.001
Mortality 2 (2.4) 0 3 (21.4) 0.01
PF, pancreatic fistula
aNo of PF compared with surgical treatment
bConservative treatment compared with surgical treatment
cOther than PF
Values in parentheses are percentages, unless otherwise indicated
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gastrectomy. Moreover, definitive endocrine insufficiency with
potential lethal severe hypoglycemia is a major pitfall of this
approach. In our experience, even in cases of reoperation, most
patients (9/14) did not undergo CP. Among the five patients who
underwent CP, splenic conservation was not possible. Two of these
(40%) patients died during the post-operative course. Overall, we
are in accordance with the mortality rate after CP ranging from
0% to 80%.32,33,35–37 However, only four studies reported their
experience of CP with a reduced number of patients. As a result of
the small sample size, no conclusion can be drawn.
On the other hand, conservative treatment is now more fre-
quently applied even in cases of diffuse peritonitis. Most of the
patients reported herein were conservatively treated even in the
case of diffuse peritonitis (3/9) with (3/9) or without associated
haemmorhagical complications. The remaining patients (3/9)
had localized abscesses which were not radiologically accessible.
Gueroult et al. speculated that CP avoids reoperation.32 However,
in their study, they did not compare CP with conservative treat-
ment. In our experience, none of the patients were reoperated
after ‘salvage’ drainage. Morever morbidity did not differ
between CP and drainage. Although the mortality rate was not
statistically significant, there is a tendency for an increased mor-
tality rate after CP (40%) as compared with drainage (11%). In
the case of leakage requiring surgical drainage, several authors
reported a mortality rate ranging from 0% to 33%,16,37–40 which
is lower than the mortality rate reported after CP (0 to 80%).
Again, the number of reoperations was similar, irrespective of
the use of CP or drainage to treat PF. Our experience, which
corroborated with several authors, shows that the conservative
approach was not related to increased reoperations when com-
pared with CP.
After PD, haemorrhage occurs in more than 10% and is
strongly related to local sepsis and anastomotic leakage.12,41 In our
study, four patients reoperated for PF had an associated haemor-
rhage, a higher rate when compared with patients without PF, or
with PF treated conservatively. The association between PF and
haemorrhage has been reported and some authors suggested that
pancreatic remnant resection is necessary to prevent rebleeding.42
In this series, three patients were treated by laparotomy without
CP and relaparotomy was not necessary. Drainage of intra-
abdominal collection and fistula may avoid pancreatic fluid
contact with dissected vessels, preventing hemorrhage.
Conclusion
This study demonstrated that the surgical approach for PF is
associated with higher mortality and morbidity rates, as compared
with the conservative approach. In case of PF requiring surgical
treatment, it seems that there is no advantage in performing a
completion as compared with extensive drainage, owing to the
same mortality and morbidity rates, and given the risk of severe
endocrine insuffiency in case of CP. Radiological or surgical con-
servative treatment of a PF should be the preferred option.
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